# Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)

> **NCT00452634** · PHASE2 · COMPLETED · sponsor: **National Cancer Center, Korea** · enrollment: 62 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Cisplatin
- **DRUG:** Simvastatin

## Key facts

- **NCT ID:** NCT00452634
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2009-11
- **Final completion:** 2010-05
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2013-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00452634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00452634, "Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00452634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*